Table 3.

Factor impact on overal survival

Factors	HR	95% CI	p-value
PSA decrease ≥ 50 %	0.388	0.122–0.930	0.038
Early PSA decrease ≥ 50 % (≤ 3 vs. > 3 months)	0.330	0.120–0.910	0.032
Primary ADT duration (> 12 vs. ≤ 12 months)	0.735	0.281–1.588	0.845
Age (< 74 vs. ≥ 74 years)	0.431	0.168–1.101	0.079
Gleason score (6–7 vs. 8–10)	0.932	0.391–2.227	0.876
PS (0 vs. 1)	0.115	0.026–0.498	0.004
Primary localized vs. metastatic disease	0.691	0.264–1.807	0.451

PSA — prostate-specific antigen; ADT — androgen deprivation therapy; PS — performance status; HR — hazard ratio; CI — confidence interval